Edwards Lifesciences Corporation ($EW) Stock Forecast: Down 3.0% Today

What is Edwards Lifesciences Corporation?

Edwards Lifesciences (NYSE: EW) is a global leader in structural heart innovation, dedicated to enhancing patient lives through cutting-edge technologies. The overall market saw a positive trading day, with the Dow Jones Industrial Average also experiencing significant gains.

Why is Edwards Lifesciences Corporation going down?

EW stock is down 3.0% on Apr 28, 2026 14:35

• Profit-taking by investors after a recent strong trading day has contributed to the bearish movement in Edwards Lifesciences (EW) stock.
• Concerns among investors about potential competition in the cardiovascular space, triggered by the pending acquisition of Penumbra by Boston Scientific, have negatively impacted EW's stock.
• Market sentiment surrounding broader industry developments, despite positive news like the CEO's upcoming presentation and increased holdings by Munich Reinsurance Co Stock Corp, has influenced the bearish movement in EW stock today.

EW Price Chart

EW Technical Analysis

EW News

Edwards CEO speaks May 12, with live webcast and same-day replay

Edwards Lifesciences (NYSE: EW) announced its CEO, Bernard Zovighian, will present at the BofA Securities 2026 Health Care Conference on May 12, 2026. The fireside chat will be webcast live on the company's investor relations website at 3:40 p.m. Pacific Time, with an archived version available later the same day. Edwards Lifesciences is a global leader in structural heart innovation, committed to improving patient lives through breakthrough technologies.

https://www.stocktitan.net/news/EW/edwards-lifesciences-to-present-at-the-bof-a-securities-2026-health-s0kbn1oui1pm.html

One Boston Scientific heart device beat drug therapy in new trial data

Boston Scientific (NYSE: BSX) presented late-breaking clinical results at Heart Rhythm 2026, highlighting the superiority of its FARAPULSE PFA platform over anti-arrhythmic drugs for persistent atrial fibrillation. The data also reinforced the safety and effectiveness of WATCHMAN LAAC devices, showing reduced non-procedural bleeding and successful combinatory procedures with PFA. Despite some study limitations, the results indicate strong clinical performance across key cardiovascular platforms.

https://www.stocktitan.net/news/BSX/data-at-heart-rhythm-2026-highlight-key-boston-scientific-i8slgxadgwi4.html

How STORM-PE Thrombectomy Results and Lightning Flash Data Will Impact Penumbra (PEN) Investors

Penumbra recently announced positive 90-day results from its STORM-PE trial, showing improved functional outcomes and comparable safety for its Lightning Flash CAVT system in treating pulmonary embolism. These results strengthen Penumbra's investment case, especially regarding broader adoption of its thrombectomy technology. However, investors also need to consider the pending acquisition by Boston Scientific, which shifts focus to closing conditions and integration risks, alongside competitive and pricing pressures.

https://simplywall.st/stocks/us/healthcare/nyse-pen/penumbra/news/how-storm-pe-thrombectomy-results-and-lightning-flash-data-w

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day

Edwards Lifesciences Corp. (EW) stock saw a gain of 1.48% to $85.60 on a strong trading day, outpacing key competitors like Medtronic PLC and Abbott Laboratories. This positive performance occurred as the Dow Jones Industrial Average also rose significantly.

http://www.msn.com/en-us/money/topstocks/edwards-lifesciences-corp-stock-outperforms-competitors-on-strong-trading-day/ar-AA21F18v?uxmode=ruby&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-t

Munich Reinsurance Co Stock Corp in Munich Purchases 52,494 Shares of Edwards Lifesciences Corporation $EW

Munich Reinsurance Co Stock Corp in Munich significantly increased its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 3,673.5%, purchasing 52,494 additional shares. This move brings their total stake to 53,923 shares valued at approximately $4.65 million. The increased stake follows Edwards Lifesciences' strong Q1 earnings beat, raised guidance for FY2026, and an announced $500 million accelerated share repurchase program, despite a recent trend of insider selling from company executives.

https://www.marketbeat.com/instant-alerts/filing-munich-reinsurance-co-stock-corp-in-munich-purchases-52494-shares-of-edwards-lifesciences-corporation-ew-2026-04-25/

Trending Today

Bitcoin ($BTC) Crypto Forecast: Up 5.1% Today

NASDAQ-100 ($NDX) Index Forecast: Down 5.2% Today

Ethereum ($ETH) Crypto Forecast: Up 5.3% Today

Edwards Lifesciences Corporation Price History

31.02.2026 - EW Stock was down 3.4%

• The bearish movement in Edwards Lifesciences Corp. (EW) stock can be attributed to profit-taking by investors after a period of sustained growth.
• Despite positive developments such as the FDA clearance for the AI heart valve repair solution developed in collaboration with Philips, the market may have reacted negatively due to high expectations already priced into the stock.
• The positive 2-year survival data from the TRISCEND II trial for the EVOQUE transcatheter tricuspid valve replacement system could have been overshadowed by broader market sentiment or sector rotation.
• Investors might be cautious about the stock's valuation, considering the recent price pressure and fluctuations, leading to the bearish movement despite the company's strong management efficiency and positive long-term performance.

11.01.2026 - EW Stock was up 1.1%

• An affirmation of a "Buy" rating for Edwards Lifesciences (EW) with a target price of $103.00 USD has enhanced investor confidence and sparked a bullish movement in the stock.
• Despite falling short of the EPS estimate by $0.04, Edwards Lifesciences delivered robust Q4 2025 sales growth, primarily from TAVR sales, and expressed optimism about its 2026 adjusted EPS and full-year sales growth forecast. This positive outlook has likely contributed to the bullish momentum.
• Strong Q4 2025 results, featuring double-digit revenue growth and positive projections for growth avenues like the LAA market, have reinforced investor confidence in Edwards Lifesciences, adding fuel to the bullish trend.
• Overall, positive analyst ratings, robust sales growth, and a promising future outlook have driven Edwards Lifesciences' stock on an upward trajectory today.

24.03.2026 - EW Stock was up 5.0%

• Despite surpassing Q1 earnings expectations and showing robust revenue growth, the market response was mixed as its Q2 and full-year outlook aligned with predictions.
• Selling activities from institutions like Teacher Retirement System of Texas and OLD National Bancorp IN, along with insider trading, might have contributed to short-term selling pressure on the stock.
• Analysts' differing views and adjustments to price targets indicate uncertainty and possible market volatility.
• The stock price target increase by Truist Securities, citing strong growth in Transcatheter Aortic Valve Replacement (TAVR) and improved revenue and earnings guidance, likely influenced the upward movement.

24.03.2026 - EW Stock was up 6.0%

• An analyst reiterated a Buy rating and raised the price target for Edwards Lifesciences following its strong Q1 results, which has positively impacted investor sentiment.
• The company has increased its full-year guidance, noting better-than-expected performance in Q1, particularly in its transcatheter aortic valve replacement (TAVR) business, driving sales growth.
• Despite some selling from insiders and institutions, likely due to profit-taking concerns related to the high P/E ratio, overall market sentiment remains positive, with many analysts revising price targets upwards, indicating confidence in the company's future.
• The market response to the guidance meeting consensus expectations may result in short-term selling pressure, but the company's solid performance and growth prospects suggest a favorable trajectory for Edwards Lifesciences.

27.02.2026 - EW Stock was down 5.3%

• Edwards Lifesciences (EW) witnessed a downward trend despite recent positive developments related to Vanguard subsidiaries' holdings in the company.
• Market sentiment towards medical device firms, exacerbated by enVVeno Medical Corp's strategic shift and regulatory hurdles, likely affected Edwards Lifesciences' stock performance.
• Heightened investor attention on Abbott Laboratories' stock following a slowdown in diagnostics may have contributed to the bearish movement in the medical technology sector, impacting companies like Edwards Lifesciences.
• Although outperforming competitors on a recent trading day, prevailing market conditions and sector-specific obstacles appear to have overshadowed the positive momentum for Edwards Lifesciences, resulting in the downward movement.

27.02.2026 - EW Stock was down 5.1%

• The bullish movement in AstraZeneca's shares could have attracted investors away from Edwards Lifesciences, impacting its stock negatively.
• The positive projections for the global cardiac ablation devices market might have shifted investor focus towards competitors in the healthcare sector, leading to a bearish trend for Edwards Lifesciences.
• Information about Vanguard reporting zero holdings in Edwards Lifesciences could have caused uncertainty among investors, contributing to the bearish movement in the stock.
• The strategic shift and challenges faced by enVVeno Medical Corp could have highlighted the competitive landscape in the healthcare industry, potentially affecting investor sentiment towards companies like Edwards Lifesciences.

28.03.2026 - EW Stock was down 3.0%

• Profit-taking by investors after a recent strong trading day has contributed to the bearish movement in Edwards Lifesciences (EW) stock.
• Concerns among investors about potential competition in the cardiovascular space, triggered by the pending acquisition of Penumbra by Boston Scientific, have negatively impacted EW's stock.
• Market sentiment surrounding broader industry developments, despite positive news like the CEO's upcoming presentation and increased holdings by Munich Reinsurance Co Stock Corp, has influenced the bearish movement in EW stock today.